<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Encounter Summary</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Reason for Visit</a></li><li><a href="#id2">Encounter Details</a></li><li><a href="#id3">Social History</a></li><li><a href="#id4">Progress Notes</a></li><li><a href="#id5">Plan of Treatment</a></li><li><a href="#id6">Visit Diagnoses</a></li><li><a href="#id7">Care Teams</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Reason for Visit</a></h3><div><ul><li><table><colgroup><col width="25%"/><col width="75%"/></colgroup><thead><tr><th>Reason</th><th>Comments</th></tr></thead><tbody><tr ID="rfv2"><td ID="reasonrfv2">Prostate Cancer</td><td/></tr></tbody></table></li><li>Other (Routine) - Closed: <table><colgroup><col width="25%" span="4"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td>Radiation Oncology</td><td><p>Diagnoses</p><p>Malignant neoplasm of prostate (HC CODE)</p><br/><p>Procedures</p><p>G2211</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>STE 330</p><p>[REDACTED]</p><p>Phone: tel:[REDACTED]</p><p>fax:[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]</p><p>Phone: tel:[REDACTED]</p><p>fax:[REDACTED]</p></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>10931628</td><td class="xflagData">Closed</td><td/><td>[REDACTED]</td><td>[REDACTED]</td><td>1</td><td>1</td></tr></tbody></table><br/></li></ul></div><h3><a name="id2" href="#toc">Encounter Details</a></h3><div><table><colgroup><col width="10%"/><col width="15%"/><col width="25%" span="3"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter4" class="xRowNormal"><td>[REDACTED]  4:30 PM EDT</td><td ID="encounter4type">Telemedicine</td><td><p>Cancer Center of [REDACTED]</p><p>[REDACTED]</p><p>[REDACTED], [REDACTED] 33609</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED], FL 33609</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td><content>Malignant neoplasm of prostate (HC CODE) (Primary Dx); <br/>PSA elevation; <br/>Secondary malignant neoplasm of bone (HC CODE); <br/>Prostate cancer metastatic to intrapelvic lymph node (HC CODE)</content></td></tr></tbody></table></div><h3><a name="id3" href="#toc">Social History</a></h3><div><table ID="sochist12"><colgroup><col width="25%" span="2"/><col width="13%"/><col width="12%"/><col width="25%"/></colgroup><thead><tr><th>Tobacco Use</th><th>Types</th><th>Packs/Day</th><th>Years Used</th><th>Date</th></tr></thead><tbody><tr><td>Smoking Tobacco: Never Assessed</td><td/><td ID="sochist12packsperday"/><td/><td/></tr></tbody></table><table><colgroup><col width="50%"/><col width="25%" span="2"/></colgroup><thead><tr><th>Sex and Gender Information</th><th>Value</th><th>Date Recorded</th></tr></thead><tbody><tr ID="BirthSex15"><td>Sex Assigned at Birth</td><td ID="BirthSex15Value">Not on file</td><td/></tr><tr ID="LegalSex16"><td>Legal Sex</td><td ID="LegalSex16Value">Male</td><td>[REDACTED]  2:06 PM EST</td></tr><tr ID="GenderIdentity13"><td>Gender Identity</td><td ID="GenderIdentity13Value">Not on file</td><td/></tr><tr ID="SexualOrientation14"><td>Sexual Orientation</td><td ID="SexualOrientation14Value">Not on file</td><td/></tr></tbody></table>documented as of this encounter</div><h3><a name="id4" href="#toc">Progress Notes</a></h3><div><ul><li>[REDACTED], MD - [REDACTED]  4:30 PM EDT: <content><content><span class="xLabel">Formatting of this note is different from the original.</span><br/>Patient Name:  [REDACTED]<br/>Date of Birth:    [REDACTED]<br/>Medical Record:  101632979<br/>Encounter Date:  [REDACTED] <br/> <br/>Subjective:<br/><br/>Chief Complaint: The patient is a [REDACTED]. male who presents with mCSPC on presentation<br/><br/>- [REDACTED] TURP: Pathology: Prostatic adenocarcinoma, grade 4 + 5 = 9 occupying approximately 50% of submitted tissue. <br/><br/>- iPSA 1,953<br/><br/>- [REDACTED] PSMA PET (Akumin): Enlargement of the prostate gland with heterogeneous intense radiotracer uptake in the parenchyma (SUV MAX 37.4) representing biopsy proven cancer. Extracapsular extension of the tumor with possible infiltration of the rectum. Left subcentimeter external iliac metastatic lymph nodes with SUV max of 16.1. Innumerable avid bone lesions in skull base, axial skeleton, and bilateral proximal femurs representing metastatic bone disease. Hyperdense and heterogeneous masses in the retromandibular regions bilaterally measuring 5.6 cm on the right and 8.8 cm on the left, indeterminate. Neck MRI without and with contrast is recommended for better characterization.<br/><br/>- Ongoing Eligard (Start 05/2024)<br/>HPI: <br/>[REDACTED] is a [REDACTED] man with prostate cancer. He has a personal medical history of HTN, HLD, urine retention, GERD, gout, COPD, and [REDACTED] esophagus. <br/><br/>He is followed by [REDACTED] at Suncoast Urology. DRE: 50 g and Benign. <br/><br/>[REDACTED] CT A/P (HCA Bayonet Point): Moderate bilateral hydronephrosis secondary due to massive urinary bladder dilation abouve the level of the umbilicus. Bladder outlet obstruction could be present. Prosatomegaly. <br/><br/>[REDACTED]<br/><br/>[REDACTED] TRUS: Moderate prostatomegaly<br/><br/>[REDACTED] TURP: Pathology: Prostatic adenocarcinoma, grade 4 + 5 = 9 occupying approximately 50% of submitted tissue. <br/><br/>[REDACTED] PSA: 1,953.0, Alk phos: 175 (H), Hgb: 11.8 (L), Hct: 35.7 (L)<br/><br/>[REDACTED] PSMA PET (Akumin): Enlargement of the prostate gland with heterogeneous intense radiotracer uptake in the parenchyma (SUV MAX 37.4) representing biopsy proven cancer. Extracapsular extension of the tumor with possible infiltration of the rectum. Left subcentimeter external iliac metastatic lymph nodes with SUV max of 16.1. Innumerable avid bone lesions in skull base, axial skeleton, and bilateral proximal femurs representing metastatic bone disease. Hyperdense and heterogeneous masses in the retromandibular regions bilaterally measuring 5.6 cm on the right and 8.8 cm on the left, indeterminate. Neck MRI without and with contrast is recommended for better characterization.<br/><br/>[REDACTED] Eligard 22.5 mg<br/><br/>[REDACTED] presents [REDACTED] via telehealth. <br/><br/> <br/><br/>Past Medical History:  <br/>No past medical history on file. <br/><br/>Surgical History:  <br/>No past surgical history on file.<br/><br/>Family History:  His family history is not on file.<br/><br/>Social History: He  <br/><br/>Tobacco History: He  has no history on file for tobacco use.<br/><br/>Allergies: [REDACTED] has no allergies on file. <br/><br/>Medications:<br/>No current outpatient medications on file. <br/>Labs: <br/>Labs in Last 3 Months No results found for this or any previous visit (from the past 2232 hour(s)).<br/> <br/> Objective:<br/>Vital signs: There were no vitals taken for this visit. <br/><br/>Physical Exam: <br/><br/>Constitutional:  <br/>   Normal appearance.  <br/>Pulmonary: <br/>   Normal respiratory effort. <br/>Psychiatric:    <br/>   Normal mood and affect. <br/>Physical Exam <br/><br/>In House Urinalysis: <br/>No results found for this or any previous visit. <br/><br/>Data Reviewed: <br/>Data reviewed during this visit:  Labs, Radiology reports, Radiology images, and Consult notes<br/>  <br/>Assessment:<br/>1. Malignant neoplasm of prostate (HC CODE)  <br/><br/>None<br/><br/>Plan:<br/>Continue on Eligard. <br/><br/>With mCSPC, secondary androgen agent indicated. Erleada Rx sent to FLUP pharmacy [REDACTED] and benefit investigation is underway. We will arrange for him to pick up at [REDACTED]' office. <br/><br/>We discussed the indication for docetaxel but he does not want to pursue chemotherapy at this time.<br/><br/>Alendronate sent to his pharmacy [REDACTED]. Calcium and vit D supplementation also encouraged for bone health while on combined androgen blockade. <br/><br/>RTC in 08/2024 with new PSA/CMP/TST to assess response.<br/>Orders Placed This Encounter <br/> COMPREHENSIVE METABOLIC PANEL (CMP), SERUM <br/> PROSTATE SPECIFIC ANTIGEN (PSA) <br/> TESTOSTERONE, FREE, TOTAL <br/> apalutamide (Erleada) 240 mg Tab <br/> alendronate (FOSAMAX) 70 mg tablet <br/>We reviewed his medical history and clinical course to date. I discussed the risk stratification, prognosis, and management options for prostate cancer as well as my partnership with [REDACTED] within [REDACTED] Urology Partners.  We discussed treatment options, including: chemotherapy, surgery and radiation therapy +/- hormone therapy and secondary androgen agent.  Expectations, risks and side effects reviewed. <br/> <br/></content><br/><span class="xLabel">Electronically signed by [REDACTED], MD at [REDACTED]  1:39 PM EDT</span><br/></content></li></ul>documented in this encounter</div><h3><a name="id5" href="#toc">Plan of Treatment</a></h3><div><table><span style="font-weight:bold; ">Scheduled Orders</span><colgroup><col width="25%"/><col width="15%"/><col width="10%"/><col width="25%" span="2"/></colgroup><thead><tr><th>Name</th><th>Type</th><th>Priority</th><th>Associated Diagnoses</th><th>Order Schedule</th></tr></thead><tbody><tr ID="procedure36"><td><span class="content_span">COMPREHENSIVE METABOLIC PANEL (CMP), SERUM</span></td><td>Lab</td><td>Routine</td><td><p>Malignant neoplasm of prostate (HC CODE)</p><p>PSA elevation</p><p>Secondary malignant neoplasm of bone (HC CODE)</p><p>Prostate cancer metastatic to intrapelvic lymph node (HC CODE)</p></td><td ID="procedure36schedule">Expected: [REDACTED] (Approximate), Expires: [REDACTED]</td></tr><tr ID="procedure37"><td><span class="content_span">PROSTATE SPECIFIC ANTIGEN (PSA)</span></td><td>Lab</td><td>Routine</td><td><p>Malignant neoplasm of prostate (HC CODE)</p><p>PSA elevation</p><p>Secondary malignant neoplasm of bone (HC CODE)</p><p>Prostate cancer metastatic to intrapelvic lymph node (HC CODE)</p></td><td ID="procedure37schedule">Expected: [REDACTED] (Approximate), Expires: [REDACTED]</td></tr><tr ID="procedure38"><td><span class="content_span">TESTOSTERONE, FREE, TOTAL</span></td><td>Lab</td><td>Routine</td><td><p>Malignant neoplasm of prostate (HC CODE)</p><p>PSA elevation</p><p>Secondary malignant neoplasm of bone (HC CODE)</p><p>Prostate cancer metastatic to intrapelvic lymph node (HC CODE)</p></td><td ID="procedure38schedule">Expected: [REDACTED] (Approximate), Expires: [REDACTED]</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id6" href="#toc">Visit Diagnoses</a></h3><div><table><colgroup><col width="100%"/></colgroup><thead><tr><th>Diagnosis</th></tr></thead><tbody><tr ID="vdx5" class="xRowNormal"><td><p><span class="content_span">Malignant neoplasm of prostate (HC CODE)</span><span class="content_span"> - Primary</span></p><p>Malignant neoplasm of prostate</p></td></tr><tr ID="vdx6" class="xRowAlt"><td><p><span class="content_span">PSA elevation</span></p><p>Elevated prostate specific antigen (PSA)</p></td></tr><tr ID="vdx7" class="xRowNormal"><td><p><span class="content_span">Secondary malignant neoplasm of bone (HC CODE)</span></p><p>Secondary malignant neoplasm of bone and bone marrow</p></td></tr><tr ID="vdx8" class="xRowAlt"><td><p><span class="content_span">Prostate cancer metastatic to intrapelvic lymph node (HC CODE)</span></p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id7" href="#toc">Care Teams</a></h3><div><table ID="ct48"><colgroup><col width="25%" span="3"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Team Member</th><th>Relationship</th><th>Specialty</th><th>Start Date</th><th>End Date</th></tr></thead><tbody><tr class="xRowNormal"><td><p>[REDACTED], MD</p><p>NPI: [REDACTED]</p><p>[REDACTED]</p><p>STE 330</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td>PCP - General</td><td>Internal Medicine</td><td>[REDACTED]</td><td/></tr><tr class="xRowAlt"><td><p>[REDACTED], MD</p><p>NPI: [REDACTED]</p><p>7614 JACQUE RD</p><p>STE A</p><p>HUDSON, FL 34667</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/><td>Urology</td><td>[REDACTED]</td><td/></tr></tbody></table>documented as of this encounter</div><br/><br/>
</body></html>